140 related articles for article (PubMed ID: 32698158)
1. Critical appraisal of MGMT in digestive NET treated with alkylating agents.
de Mestier L; Couvelard A; Blazevic A; Hentic O; de Herder WW; Rebours V; Paradis V; Ruszniewski P; Hofland LJ; Cros J
Endocr Relat Cancer; 2020 Oct; 27(10):R391-R405. PubMed ID: 32698158
[TBL] [Abstract][Full Text] [Related]
2. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
[TBL] [Abstract][Full Text] [Related]
3. O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).
Lemelin A; Barritault M; Hervieu V; Payen L; Péron J; Couvelard A; Cros J; Scoazec JY; Bin S; Villeneuve L; Lombard-Bohas C; Walter T;
Dig Liver Dis; 2019 Apr; 51(4):595-599. PubMed ID: 30824408
[TBL] [Abstract][Full Text] [Related]
4. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Cros J; Hentic O; Rebours V; Zappa M; Gille N; Theou-Anton N; Vernerey D; Maire F; Lévy P; Bedossa P; Paradis V; Hammel P; Ruszniewski P; Couvelard A
Endocr Relat Cancer; 2016 Aug; 23(8):625-33. PubMed ID: 27353036
[TBL] [Abstract][Full Text] [Related]
5. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
[TBL] [Abstract][Full Text] [Related]
6. Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis.
Qi Z; Tan H
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32141507
[TBL] [Abstract][Full Text] [Related]
7. Should temozolomide be used on the basis of O
Trillo Aliaga P; Spada F; Peveri G; Bagnardi V; Fumagalli C; Laffi A; Rubino M; Gervaso L; Guerini Rocco E; Pisa E; Curigliano G; Fazio N
Cancer Treat Rev; 2021 Sep; 99():102261. PubMed ID: 34332293
[TBL] [Abstract][Full Text] [Related]
8. O
Watanabe H; Yamazaki Y; Fujishima F; Izumi K; Imamura M; Hijioka S; Toriyama K; Yatabe Y; Kudo A; Motoi F; Unno M; Sasano H
BMC Cancer; 2020 Dec; 20(1):1195. PubMed ID: 33287738
[TBL] [Abstract][Full Text] [Related]
9. Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET.
Hijioka S; Sakuma K; Aoki M; Mizuno N; Kuwahara T; Okuno N; Hara K; Yatabe Y
Cancer Chemother Pharmacol; 2019 Jan; 83(1):43-52. PubMed ID: 30310970
[TBL] [Abstract][Full Text] [Related]
10. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
[TBL] [Abstract][Full Text] [Related]
12. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
13. Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?
Hiddinga B; Zwaenepoel K; Janssens A; Van Meerbeeck J; Pauwels P
Oncotarget; 2022; 13():800-809. PubMed ID: 35677534
[TBL] [Abstract][Full Text] [Related]
14. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
[TBL] [Abstract][Full Text] [Related]
15. Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.
Campana D; Walter T; Pusceddu S; Gelsomino F; Graillot E; Prinzi N; Spallanzani A; Fiorentino M; Barritault M; Dall'Olio F; Brighi N; Biasco G
Endocrine; 2018 Jun; 60(3):490-498. PubMed ID: 29150792
[TBL] [Abstract][Full Text] [Related]
16. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents.
Walter T; van Brakel B; Vercherat C; Hervieu V; Forestier J; Chayvialle JA; Molin Y; Lombard-Bohas C; Joly MO; Scoazec JY
Br J Cancer; 2015 Feb; 112(3):523-31. PubMed ID: 25584486
[TBL] [Abstract][Full Text] [Related]
17. O
Hiddinga BI; Pauwels P; Janssens A; van Meerbeeck JP
Lung Cancer; 2017 May; 107():91-99. PubMed ID: 27492578
[TBL] [Abstract][Full Text] [Related]
18. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
[TBL] [Abstract][Full Text] [Related]
19. Multiple Assays to Determine Methylguanine-Methyltransferase Status in Lung Carcinoids and Correlation with Clinical and Pathological Features.
Vatrano S; Giorcelli J; Votta A; Capone G; Izzo S; Gatti G; Righi L; Napoli F; Scagliotti G; Papotti M; Volante M; Rapa I
Neuroendocrinology; 2020; 110(1-2):1-9. PubMed ID: 31280263
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice.
Dussol AS; Joly MO; Vercherat C; Forestier J; Hervieu V; Scoazec JY; Lombard-Bohas C; Walter T
Cancer; 2015 Oct; 121(19):3428-34. PubMed ID: 26058464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]